4basebio’s full-year results to 31 December 2021 reflect consistent progress towards its main objectives, with recently completed clean rooms undergoing validation ahead of targeted DNA production towards the year end. It generated revenues of £0.34m with a pre-tax loss of £3.64m (FY 2020: £0.72m) and ended the period with £9.6m cash, providing it with a cash runway into 2023 and an undrawn loan facility of €25m. When fully operational, this facility will be able to produce DNA with a value in e ....
09 May 2022
4basebio - FY 2021 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
4basebio - FY 2021 results
4basebio PLC (4BB:LON) | 1,045 0 0.0% | Mkt Cap: 133.8m
- Published:
09 May 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
12
4basebio’s full-year results to 31 December 2021 reflect consistent progress towards its main objectives, with recently completed clean rooms undergoing validation ahead of targeted DNA production towards the year end. It generated revenues of £0.34m with a pre-tax loss of £3.64m (FY 2020: £0.72m) and ended the period with £9.6m cash, providing it with a cash runway into 2023 and an undrawn loan facility of €25m. When fully operational, this facility will be able to produce DNA with a value in e ....